Profil
Matilda Bingham is currently working as an Executive Director at Redx Oncology Ltd.
since 2015.
Prior to this, she worked as the Head of Research & Operations at Redx Pharma Plc.
Aktive Positionen von Matilda Bingham
| Unternehmen | Position | Beginn |
|---|---|---|
Redx Oncology Ltd.
 Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | Direktor/Vorstandsmitglied | 05.11.2015 |
Ehemalige bekannte Positionen von Matilda Bingham
| Unternehmen | Position | Ende |
|---|---|---|
| REDX PHARMA PLC | Geschäftsführer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| REDX PHARMA PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Redx Oncology Ltd.
Redx Oncology Ltd. Pharmaceuticals: MajorHealth Technology Part of Redmile Group LLC, Redx Oncology Ltd. is a British biotech company focused on discovering and developing novel targeted medicines for the treatment of cancer and fibrotic disease. The company is based in Macclesfield, UK, and the CEO of the company is Derek Lindsay. The company's focus is on small molecule inhibitors for fibrotic diseases, with preclinical proof of concept demonstrated in lung and kidney fibrosis models. Redx Pharma recently signed an agreement with Jazz Pharmaceuticals for the potential treatment of raf and ras mutant tumors. | Health Technology |